![]() We defined poor Ab response as ‘undetectable’ if Ab levels are ≤0.80 U/mL and ‘low’ if levels are between 0.80 U/mL and 249.9 U/mL. We studied LT recipients and those with CLD (with or without cirrhosis) who had poor antibody response to SARS-CoV-2 spike protein after 2 doses of mRNA vaccines or a single dose of JnJ vaccine. In this prospective study, we assessed the antibody (Ab) responses after a booster dose with either mRNA (Pfizer/Moderna) or Johnson & Johnson (JnJ) vaccine in LT recipients and those with CLD who had low Ab levels after the initial standard regimen as recommended by the manufacturers. However, the Ab responses in those who fail to mount a good response after the initial vaccination have not been well established. The Center for Disease Control and Prevention has recently recommended booster dose for immunocompromised and elderly patient population 6-8 months after the initial vaccination. Other studies have corroborated the above observations in organ transplant recipients. In our study, most patients with CLD who had poor Ab responses were on immunosuppressants, and immunosuppression, including the number of immunosuppressants, was an independent predictor for lower Ab responses. In a previous study, we had reported that 61% of LT recipients and 24% of those with CLD had poor Ab response to spike proteins after receiving a standard regimen of SARS-CoV-2 vaccine. Poor antibody (Ab) responses to standard vaccination against SARS-CoV-2 have been observed in liver transplant (LT) recipients and those with chronic liver diseases (CLD). We have shown that a booster dose will enhance Ab responses in LT recipients and those with CLD who had poor responses after an initial vaccine regimen. The antibody responses after homologous and heterologous booster doses were similar. The antibody responses were lower in those who had undetectable Ab (80 U/mL) than those who had low levels of Ab (0.80-249 U/mL) after the standard vaccination regimen (42% vs. No patient had any serious adverse events. After the booster dose, 58 (73%, 31 LT, 27 CLD) had good response (≥250 U/mL), and 22 (28%, 14 LT, and 8 CLD) had poor response (7 undetectable and 15 with low Ab levels). A booster dose was given at a median of 138.5 days after the completion of the standard regimen. Of the 80 patients enrolled, 45 had LT, and 35 had CLD (18 with cirrhosis). In this prospective study, we determined antibody (Ab) response to spike protein after a booster dose in LT recipients and those with chronic liver diseases (CLD) with and without cirrhosis after they had a poor response to an initial standard regimen. The role of a booster dose in those with poor responses to initial vaccination is not well defined. Lower antibody (Ab) responses after SARS-CoV-2 vaccination have been reported in liver transplant (LT) recipients and those with chronic liver diseases (CLD). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease. Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). ![]() AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology. ![]() It is the official journal of the Mexican Association of Hepatology ( AMH), the Latin American Association for the Study of the Liver ( ALEH), the Canadian Association for the Study of the Liver ( CASL) and the Czech Society of Hepatology ( CSH). Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |